company background image
FLB

Standard BioTools DB:FLB Stock Report

Last Price

€1.93

Market Cap

€150.6m

7D

4.6%

1Y

-32.6%

Updated

31 Jan, 2023

Data

Company Financials

FLB Stock Overview

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide.

FLB fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Standard BioTools Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Standard BioTools
Historical stock prices
Current Share PriceUS$1.93
52 Week HighUS$3.59
52 Week LowUS$0.92
Beta1.31
1 Month Change72.27%
3 Month Change58.75%
1 Year Change-32.65%
3 Year Change-45.42%
5 Year Changen/a
Change since IPO-83.22%

Recent News & Updates

Recent updates

Shareholder Returns

FLBDE Life SciencesDE Market
7D4.6%2.6%0.3%
1Y-32.6%-19.9%-11.1%

Return vs Industry: FLB underperformed the German Life Sciences industry which returned -18.5% over the past year.

Return vs Market: FLB underperformed the German Market which returned -10.1% over the past year.

Price Volatility

Is FLB's price volatile compared to industry and market?
FLB volatility
FLB Average Weekly Movement14.1%
Life Sciences Industry Average Movement6.0%
Market Average Movement5.2%
10% most volatile stocks in DE Market10.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: FLB is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: FLB's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1999615Michael Egholmhttps://www.fluidigm.com

Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Standard BioTools Inc. Fundamentals Summary

How do Standard BioTools's earnings and revenue compare to its market cap?
FLB fundamental statistics
Market Cap€150.59m
Earnings (TTM)-€164.73m
Revenue (TTM)€100.66m

1.5x

P/S Ratio

-0.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
FLB income statement (TTM)
RevenueUS$109.19m
Cost of RevenueUS$98.00m
Gross ProfitUS$11.19m
Other ExpensesUS$189.87m
Earnings-US$178.68m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.25
Gross Margin10.25%
Net Profit Margin-163.64%
Debt/Equity Ratio26.0%

How did FLB perform over the long term?

See historical performance and comparison